OBJECTIVES: To evaluate the association between ABO blood group and prognosis in patients with renal cell carcinoma (RCC) undergoing surgery. MATERIALS AND METHODS: A review of the nephrectomy database of the Asan Medical Center identified 3,172 consecutive patients who underwent nephrectomy for RCC between 1997 and 2012. Patients were followed up for a median 60.2 months (interquartile range 33-102 months). Recurrence-free (RFS), cancer-specific (CSS), and overall survival (OS) were calculated by the Kaplan-Meier method and compared using the log-rank test. A Cox proportional hazards regression model was used to estimate the prognostic significance of each variable. RESULTS: Of these 3,172 patients, 915 (28.8 %), 1,057 (33.7 %), 860 (26.7 %) and 340 (10.8 %) were blood types O, A, B, and AB, respectively. ABO blood group was not associated with age, sex, operation method, American Society of Anesthesiologists physical status classification, histologic subtype, or pathological TNM stage. The 5-year OS rates in patients with blood types O, A, B, and AB were 86.0, 86.8, 86.6, and 88.6 %, respectively, and the 10-year OS rates were 78.7, 78.6, 79.1, and 76.9 %, respectively (P = 0.990). ABO blood group was not significantly associated with RFS (P = 0.921) or CSS (P = 0.808). Univariable and multivariable analyses showed that ABO blood group was not a significant prognostic factor of RFS, CSS, or OS. CONCLUSIONS: Our study found that ABO blood group is not associated with survival outcomes and is not a prognostic factor in patients who underwent surgery for RCC.
OBJECTIVES: To evaluate the association between ABO blood group and prognosis in patients with renal cell carcinoma (RCC) undergoing surgery. MATERIALS AND METHODS: A review of the nephrectomy database of the Asan Medical Center identified 3,172 consecutive patients who underwent nephrectomy for RCC between 1997 and 2012. Patients were followed up for a median 60.2 months (interquartile range 33-102 months). Recurrence-free (RFS), cancer-specific (CSS), and overall survival (OS) were calculated by the Kaplan-Meier method and compared using the log-rank test. A Cox proportional hazards regression model was used to estimate the prognostic significance of each variable. RESULTS: Of these 3,172 patients, 915 (28.8 %), 1,057 (33.7 %), 860 (26.7 %) and 340 (10.8 %) were blood types O, A, B, and AB, respectively. ABO blood group was not associated with age, sex, operation method, American Society of Anesthesiologists physical status classification, histologic subtype, or pathological TNM stage. The 5-year OS rates in patients with blood types O, A, B, and AB were 86.0, 86.8, 86.6, and 88.6 %, respectively, and the 10-year OS rates were 78.7, 78.6, 79.1, and 76.9 %, respectively (P = 0.990). ABO blood group was not significantly associated with RFS (P = 0.921) or CSS (P = 0.808). Univariable and multivariable analyses showed that ABO blood group was not a significant prognostic factor of RFS, CSS, or OS. CONCLUSIONS: Our study found that ABO blood group is not associated with survival outcomes and is not a prognostic factor in patients who underwent surgery for RCC.
Authors: Michael E Breimer; Johan Mölne; Gunnela Nordén; Lennart Rydberg; Gilbert Thiel; Christian T Svalander Journal: Transplantation Date: 2006-08-27 Impact factor: 4.939
Authors: Brian M Wolpin; Peter Kraft; Mousheng Xu; Emily Steplowski; Martin L Olsson; Alan A Arslan; H Bas Bueno-de-Mesquita; Myron Gross; Kathy Helzlsouer; Eric J Jacobs; Andrea LaCroix; Gloria Petersen; Rachael Z Stolzenberg-Solomon; Wei Zheng; Demetrius Albanes; Naomi E Allen; Laufey Amundadottir; Melissa A Austin; Marie-Christine Boutron-Ruault; Julie E Buring; Federico Canzian; Stephen J Chanock; J Michael Gaziano; Edward L Giovannucci; Göran Hallmans; Susan E Hankinson; Robert N Hoover; David J Hunter; Amy Hutchinson; Kevin B Jacobs; Charles Kooperberg; Julie B Mendelsohn; Dominique S Michaud; Kim Overvad; Alpa V Patel; Maria-José Sanchéz; Leah Sansbury; Xiao-Ou Shu; Nadia Slimani; Geoffrey S Tobias; Dimitrios Trichopoulos; Paolo Vineis; Kala Visvanathan; Jarmo Virtamo; Jean Wactawski-Wende; Joanne Watters; Kai Yu; Anne Zeleniuch-Jacquotte; Patricia Hartge; Charles S Fuchs Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-10-22 Impact factor: 4.254
Authors: Brian M Wolpin; Andrew T Chan; Patricia Hartge; Stephen J Chanock; Peter Kraft; David J Hunter; Edward L Giovannucci; Charles S Fuchs Journal: J Natl Cancer Inst Date: 2009-03-10 Impact factor: 13.506
Authors: Samuel D Kaffenberger; Todd M Morgan; Kelly L Stratton; Adu M Boachie; Daniel A Barocas; Sam S Chang; Michael S Cookson; S Duke Herrell; Joseph A Smith; Peter E Clark Journal: BJU Int Date: 2012-09-07 Impact factor: 5.588
Authors: Andrew D Paterson; Maria F Lopes-Virella; Daryl Waggott; Andrew P Boright; S Mohsen Hosseini; Rickey E Carter; Enqing Shen; Lucia Mirea; Bhupinder Bharaj; Lei Sun; Shelley B Bull Journal: Arterioscler Thromb Vasc Biol Date: 2009-09-03 Impact factor: 8.311